Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OnCARlytics - Imugene

Next Previous
Drug Profile

OnCARlytics - Imugene

Alternative Names: CF33-CD19 - Imugene

Latest Information Update: 20 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; Imugene
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action CD19 antigen expression stimulants; Cell death stimulants; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Mar 2026 Imugene Limited terminates phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Second-line therapy or greater) in USA (Intratumoural) due to portfolio prioritisation (NCT06063317)
  • 04 Mar 2026 Imugene Limited terminates phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Second-line therapy or greater) in USA (IV) due to portfolio prioritisation (NCT06063317)
  • 28 Nov 2025 JW Therapeutics plans a phase I trial for Cancer in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top